Related Experiment Videos
Insulin resistance in myotonic dystrophy.
M G Piccardo1, G Pacini, M Rosa
12nd Medical Clinic, University La Sapienza of Rome, Italy.
Enzyme
|January 1, 1991
Summary
Myotonic dystrophy patients exhibit reduced insulin sensitivity but compensate with increased insulin secretion. This pancreatic response aims to overcome insulin resistance, particularly during the second phase of secretion.
Area of Science:
- Endocrinology
- Metabolic Research
- Genetics
Background:
- Myotonic dystrophy (MyD) is a multisystem disorder with potential metabolic complications.
- Understanding glucose metabolism and insulin dynamics is crucial for managing MyD patients.
Purpose of the Study:
- To comprehensively assess insulin secretion rates and tissue insulin sensitivity in myotonic dystrophy patients.
- To elucidate the compensatory mechanisms involved in glucose homeostasis in MyD.
Main Methods:
- Utilized the minimal model approach for analyzing frequently sampled intravenous glucose tolerance test (FSIGT) data.
- Quantified key parameters including insulin sensitivity index (SI), glucose disappearance rate (SG), and insulin secretion sensitivities (phi 1, phi 2).
Main Results:
- MyD patients demonstrated significantly reduced insulin sensitivity (SI) compared to controls.
- Glucose disappearance (SG) and glucose disappearance constant (KG) were within normal ranges, indicating normal glucose tolerance.
- Both first (phi 1) and second (phi 2) phase insulin secretion sensitivities were elevated in MyD patients, suggesting an increased pancreatic response.
Conclusions:
- Myotonic dystrophy is associated with significant insulin resistance.
- Patients with MyD compensate for insulin resistance through enhanced insulin secretion, particularly in the second phase.
- The pancreatic response aims to maintain normal glucose tolerance despite underlying insulin resistance.